Malin Corporation

Malin Corporation Interest Expense

The Interest Expense of Malin Corporation (MLC.IR) as of Oct 19, 2026 is 19.10 M EUR. In the previous year, Interest Expense was 3.20 M EUR — a change of 496.88% (higher).

Interest Expense

19.10 MEUR

YoY

496.88%

Last updated:

Interest Expense of Malin Corporation is 2022 19.10 M EUR. Interest Expense of Malin Corporation was 2021 3.20 M EUR. It decreases by 496.88% higher compared to the previous year.

The Malin Corporation Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2015
-4.30 M EUR
Jan 1, 2016
-30.10 M EUR
Jan 1, 2017
-44.70 M EUR
Jan 1, 2018
-21.20 M EUR
Jan 1, 2019
2.80 M EUR
Jan 1, 2020
96.80 M EUR
Jan 1, 2021
3.20 M EUR
Jan 1, 2022
19.10 M EUR
The Malin Corporation Interest Expense history
YEARInterest ExpenseYoY
19.10 MEUR+496.88%
3.20 MEUR-96.69%
96.80 MEUR+3,357.14%
2.80 MEUR-113.21%
-21.20 MEUR-52.57%
-44.70 MEUR+48.50%
-30.10 MEUR+600.00%
-4.30 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Malin Corporation Stock analysis

What does Malin Corporation do? Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development. Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization. The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics. Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy. Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections. Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes. The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise. Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market. Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives. Malin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Malin Corporation stock

Interest Expense of Malin Corporation is 19.10 M EUR in 2022.

Interest Expense of Malin Corporation changed from 3.20 M EUR to 19.10 M EUR, representing a 496.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Malin Corporation since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Malin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Malin Corporation

All Key Metrics — Malin Corporation